| Harish Sanjeer Lecamwasam, MD | |
|
593 Eddy St, Providence, RI 02903 | |
| (401) 444-5172 | |
| (401) 444-5090 |
| Full Name | Harish Sanjeer Lecamwasam |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 26 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386614576 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LC0200X | Anesthesiology - Critical Care Medicine | MD16318 (Rhode Island) | Secondary |
| 207L00000X | Anesthesiology | MD16318 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
News Archive
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.
The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
› Verified 1 days ago
| Entity Name | The Miriam Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770520462 PECOS PAC ID: 6901796408 Enrollment ID: O20040624000947 |
News Archive
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.
The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
› Verified 1 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.
The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
› Verified 1 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053782466 PECOS PAC ID: 2567455082 Enrollment ID: O20160121000235 |
News Archive
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.
The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harish Sanjeer Lecamwasam, MD 117 Ellenfield St Ste 101, Providence, RI 02905-4513 Ph: (401) 444-6779 | Harish Sanjeer Lecamwasam, MD 593 Eddy St, Providence, RI 02903 Ph: (401) 444-5172 |
News Archive
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.
The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
› Verified 1 days ago
Dr. Keith-austin Scarfo, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 6, Providence, RI 02903 Phone: 401-444-3777 Fax: 401-444-7249 | |
Dr. William Arthur Yelle, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 401-456-2000 | |
Dr. Joshua Kenneth Potvin, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-606-4286 Fax: 401-444-5090 | |
Dr. Henry Huang, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5172 Fax: 401-444-5090 | |
Jonathan D Uri, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Joseph Caiati, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Bruce Winter, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 101 Dudley St, Women & Infants Hospital, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7533 |